Regenxbio Inc RGNX

NAS: RGNX | ISIN: US75901B1070   2/05/2024
16,64 USD (+2,72%)
(+2,72%)   2/05/2024

1 mei 2024 · REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights · Persbericht

24 april 2024 · REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit · Persbericht

28 maart 2024 · REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD · Persbericht

27 maart 2024 · REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days · Persbericht

11 maart 2024 · REGENXBIO to Participate in Upcoming Investor Conferences · Persbericht

7 maart 2024 · REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants · Persbericht

6 maart 2024 · REGENXBIO Announces Proposed Public Offering of Common Stock · Persbericht

5 maart 2024 · Regenxbio Announces New Positive Initial Efficacy Data From Affinity Duchenne® Trial · Persbericht

29 februari 2024 · REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial · Persbericht

27 februari 2024 · REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights · Persbericht

21 februari 2024 · REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights · Persbericht

7 februari 2024 · REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint · Persbericht

7 februari 2024 · REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial · Persbericht

31 januari 2024 · REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024 · Persbericht

16 januari 2024 · REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery · Persbericht

10 januari 2024 · REGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 Meeting · Persbericht

8 januari 2024 · U.S. District Court Issues Decision on REGENXBIO and University of Pennsylvania NAV® Technology Patent Infringement Lawsuit · Persbericht

8 november 2023 · REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial Results · Persbericht

7 november 2023 · REGENXBIO to Participate in Upcoming Investor Conferences · Persbericht

3 november 2023 · REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery · Persbericht

Mijn selecties